Browse > Article

Factors Associated with Early Death in Patients with Community-Acquired Pneumonia  

Park, Hun-Pyo (Department of Medicine, Keimyung University School of Medicine)
Seo, Yong-Woo (Department of Medicine, Keimyung University School of Medicine)
Lee, Jeong-Eun (Department of Medicine, Keimyung University School of Medicine)
Kim, Young-Ho (Department of Medicine, Keimyung University School of Medicine)
Jang, Young-Yun (Department of Medicine, Keimyung University School of Medicine)
Park, Soon-Hyo (Department of Medicine, Keimyung University School of Medicine)
Seo, Chang-Kyun (Department of Medicine, Keimyung University School of Medicine)
Jeon, Young-June (Department of Medicine, Keimyung University School of Medicine)
Lee, Mi-Young (Department of Preventive Medicine, Keimyung University School of Medicine)
Choi, Won-Il (Department of Medicine, Keimyung University School of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.58, no.6, 2005 , pp. 607-613 More about this Journal
Abstract
Background : Early death is an important problem associated with the management of community-acquired pneumonia. However, there is little information on the risk factors associated with it. The aim of this study was to identify the factors associated with early death in community-acquired pneumonia patients. Methods : From January 1999 to July 2004, 1,487 adult patients with community-acquired pneumonia who were admitted to the pulmonary department via emergency center were examined. Early death was defined as those who died within 2 days of hospitalization. The clinical and laboratory aspects of the patients who died early (n = 30) were compared with those of an age and gender matched control population (n = 60). Results : In the early death group, respiratory rate, heart rate, and blood urea nitrogen (BUN) were significant higher (p < 0.05 for all), while the arterial pH, systolic pressure, and $PaO_2$ were significant lower (p < 0.05 for all) than the control. The independent factor significantly associated with early death was tachypnea (OR, 7.049). Conclusion : The importance of an early clinical assessment in emergency center with community-acquired pneumonia needs to be emphasized in order to recognize patients at risk of early death.
Keywords
Community-acquired pneumonia; Clinical manifestation; Tachypnea;
Citations & Related Records

Times Cited By SCOPUS : 1
연도 인용수 순위
1 Ortqvist A, Sterner G, Nilsson JA. Severe community-acquired pneumonia: factors influencing need of intensive care treatment and prognosis. Scand J Infect Dis 1985;17:377-86
2 The British Thoracic Society and the Public Health Laboratory Service. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. Q J Med 1987;62:195-220
3 Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54   DOI
4 Menendez R, Torres A, Zalacain R, Aspa J, Martin Villasclaras JJ, Borderias L, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004;59:960-5   DOI   ScienceOn
5 Roson B, Carratala J, Fernandez-Sabe N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004;164:502-8   DOI   ScienceOn
6 Riley PD, Aronsky D, Dean NC. Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia. Crit Care Med 2004;32:2398-402   DOI   ScienceOn
7 Finch R, Schurmann D, Collins O, Kubin R, McGivern J, Bobbaers H, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002;46:1746-54   DOI   ScienceOn
8 Baldwin DR, Andrews JM, Wise R, Honeybourne D. Bronchoalveolar distribution of cefuroxime axetil and in-vitro efficacy of observed concentrations against respiratory pathogens. J Antimicrob Chemother 1992;30:377-85   DOI   PUBMED
9 Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J 1999;14:221-9   DOI   ScienceOn
10 Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999;281:61-6   DOI   ScienceOn
11 Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989;11:586-99   DOI
12 Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987;1:671-4
13 Wise R, Honeybourne D. Antibiotic penetration into the respiratory tract: a basis for rational therapy. J Antimicrob Chemother 1995;4:28-32
14 Pachon J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A. Severe community-acquired pneumonia: etiology, prognosis, and treatment. Am Rev Respir Dis 1990;142:369-73   DOI   ScienceOn
15 Woo JH, Kang JM, Kim YS, Shin WS, Ryu JH, Choi JH, et al. A prospective multicenter study of community-acquired pneumonia in adults with emphasis on bacterial etiology. Korean J Infect Dis 2001;33:1-7
16 Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996;275:134-41   DOI   ScienceOn
17 Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562-72   DOI   ScienceOn
18 Niederman MS, Bass JB Jr, Campbell GD, Fein AM, Grossman RF, Mandell LA, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148:1418-26   DOI   ScienceOn
19 Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991;115:428-36   DOI   ScienceOn
20 Karalus NC, Cursons RT, Leng RA, Mahood CB, Rothwell RP, Hancock B, et al. Community acquired pneumonia: aetiology and prognostic index evaluation. Thorax 1991;46:413-8   DOI   ScienceOn
21 Cook PJ, Andrews JM, Wise R, Honeybourne D. Distribution of cefdinir, a third generation cephalosporin antibiotic, in serum and pulmonary compartments. J Antimicrob Chemother 1996;37:331-9   DOI   PUBMED
22 Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77   DOI   ScienceOn
23 Minino AM, Smith BL. Deaths: preliminary data for 2000. Natl Vital Stat Rep 2001;49:1-40
24 Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50   DOI   ScienceOn
25 Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-42   DOI   ScienceOn